Photo: oserlab.dana-farber.org
Apr 6, 2025, 07:34
Shilpa Singh Presents Cancer Research on SCLC Treatment Strategy
LUNGevity Foundation shared a post on X:
“Great talk by Dr. Shilpa Singh looking at Cyclin A/B RxL Macrocyclic Inhibitors in SCLC with high E2F activity.
Beautiful example of bridging lab to clinical research. Phase 1 trial is recruiting.”
More posts featuring LUNGevity Foundation.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 8, 2025, 10:36
Jun 8, 2025, 10:14
Jun 8, 2025, 10:02
Jun 8, 2025, 09:53